ANI Pharmaceuticals and Sofgen Announce FDA Approval of Nimodipine 30mg Capsules

ANI Pharmaceuticals, Inc. announced that its ANDA collaboration partner Sofgen has received approval from the FDA of the Abbreviated New Drug Application (ANDA) for Nimodipine 30mg Capsules.

“This represents ANI's first ANDA approval with our partner Sofgen,” says Arthur S. Przybyl, president and CEO of ANI, in a released statement. “We are excited to have achieved this milestone and look forward to a successful launch.”

Life & More Issues Nationwide Voluntary Recall of Akttive High Performance Fat Burner Gold Capsules

Life & More, L.L.C. is voluntarily recalling 783 Bottles from Lot #000185004400 Akttive High Performance Fat Burner Gold capsules weight loss supplements, reports the FDA. Akttive High Performance Fat Burner Gold weight loss supplement capsules are marketed as a dietary supplement for weight loss. They are packaged in aluminum bottles containing 30 gold capsules per bottle and labeled with Lot #000185004400, UPC 859189005005, Expiration 12/17.

Pain Therapeutics Lands Patents for Extended-release Oxycodone Capsules

The patents cover the company's REMOXY extended-release oxycodone capsules.

Pain Therapeutics Inc. a biopharmaceutical company, today announced the issuance of four patents by the U.S. Patent and Trademark Office covering REMOXY (oxycodone) Extended-Release Capsules CII. These patents are the result of joint inventive work by scientists from both Pain Therapeutics and Durect Corporation. The four issued patents are licensed exclusively to Pain Therapeutics in the United States and international markets with regards to four opioid drugs.

No votes yet
Syndicate content